Growing community of inventors

Barcelona, Spain

Julio Castro Palomino

Average Co-Inventor Count = 4.17

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 13

Julio Castro PalominoLuc Marti Clauzel (4 patents)Julio Castro PalominoDamiá Tormo Carulla (4 patents)Julio Castro PalominoAndrés Gagete Mateos (2 patents)Julio Castro PalominoAndrés Gagete Mateos (2 patents)Julio Castro PalominoAndres Gagete Mateos (2 patents)Julio Castro PalominoDamia Tormo Carulla (2 patents)Julio Castro PalominoMatthew Colin Thor Fyfe (1 patent)Julio Castro PalominoMarc Martinell Pedemonte (1 patent)Julio Castro PalominoTamara Maes (1 patent)Julio Castro PalominoJonathan Alleman Baker (1 patent)Julio Castro PalominoJonathan Alleman Baker (0 patent)Julio Castro PalominoJulio Castro Palomino (5 patents)Luc Marti ClauzelLuc Marti Clauzel (4 patents)Damiá Tormo CarullaDamiá Tormo Carulla (4 patents)Andrés Gagete MateosAndrés Gagete Mateos (6 patents)Andrés Gagete MateosAndrés Gagete Mateos (2 patents)Andres Gagete MateosAndres Gagete Mateos (2 patents)Damia Tormo CarullaDamia Tormo Carulla (2 patents)Matthew Colin Thor FyfeMatthew Colin Thor Fyfe (19 patents)Marc Martinell PedemonteMarc Martinell Pedemonte (18 patents)Tamara MaesTamara Maes (8 patents)Jonathan Alleman BakerJonathan Alleman Baker (4 patents)Jonathan Alleman BakerJonathan Alleman Baker (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Artax Biopharma Inc. (3 from 7 patents)

2. Oryzon Genomics S.a. (1 from 30 patents)

3. Artex Biopharma Inc. (1 from 1 patent)


5 patents:

1. 11505526 - Aryl-piperidine derivatives

2. 11434239 - Aza-dihydro-acridone derivatives

3. 10131647 - Chromene derivatives substituted by alkoxide as inhibitors of the TCR-Nck interaction

4. 10106518 - Chromene derivatives as inhibitors of TCR-Nck interaction

5. 9908859 - Lysine demethylase inhibitors for myeloproliferative disorders

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/11/2025
Loading…